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BACKGROUND

RESULTS

DISCUSSION

● Staphylococcus aureus bacteremia (SAB) increases rates of morbidity and
mortality and requires rapid and appropriate antimicrobial selection to
resolve symptoms and remove the infection
● Treatment of choice is a β-lactam or vancomycin for MSSA and MRSA
bacteremia, respectively
● Uncomplicated SAB:
○ Short-course treatment with systemic antibiotics for 14 days
○ Long-course treatment for 28 days is preferred to eliminate potential for
complications and relapse
● Complicated SAB:
○ Long-course treatment is recommended at ≥ 4 weeks

 Eight patients at Wellstar North Fulton hospital presented with S. aureus bacteremia during January, 2017 to June,

● Complete data collection and analysis at all Wellstar facilities pending
● At Wellstar North Fulton hospital, primary outcome of appropriate treatment of SAB
based on appropriate antibiotic selection and appropriate duration of therapy was
met in 71% (5 out of 7) patients
○ However, one patient expired prior to the completion of therapy. Primary
outcome was met in 83% (5 out of 6) patients if excluding that patient.
○ One patient who qualified for long-course treatment received only a short course
● Vancomycin was the most common agent used for MRSA bacteremia. Alternatives
included daptomycin, ceftaroline, and linezolid based on concurrent infections
● Vancomycin was started initially for the MSSA patients but later changed to
ceftriaxone or nafcillin upon confirmation of MSSA. Some patients also received
piperacillin/tazobactam or meropenem for MSSA for concurrent Gram-negative and
anaerobic coverage
● Difference in outcomes due to the presence of ID consultation was difficult to
assess in this small subset of patients.
○ Upon completion of data collection/assessment at all facilities, these outcomes
will be evaluated



2017
One patient was excluded as care was withdrawn prior to the completion of targeted therapy

Primary Outcome:

 Percentage of patients treated appropriately for SAB based on:
o Antibiotic selection: 7 out of 7 patients
o Duration of therapy: 5 out of 7 patients
Primary Outcome: Appropriate
Selection of Antibiotics and Duration

Primary Outcome: Appropriate
Selection of Antibiotics Alone

OBJECTIVE
● To assess appropriate treatment of SAB (by antibiotic selection and
duration of therapy) and to determine if targeted therapy, relapse or SABrelated readmission, length of stay, and mortality rates were affected by
the presence of an Infectious Disease (ID) consultation
○ Primary Outcome
 Percentage of patients treated appropriately for SAB (by antibiotic
selection and duration of therapy)
○ Secondary Outcomes
 Antimicrobial stewardship interventions
 Timing of ID consults
 Difference in outcomes due to presence of an ID consult
• Appropriate targeted therapy
• Recurrence or SAB-related readmission, length of stay, and
mortality rate

METHODS
● A retrospective chart review was conducted by Wellstar hospital system in
the greater Atlanta area from January 1 to June 30 in 2017
● Patients were identified from microbiology reports of positive blood cultures
with S.aureus
● Information collected includes baseline characteristics, selection and
duration of antibiotic therapy, presence of ID consultations, and follow up
reports of complications post therapy
● Patient Population
○ Inclusion criteria
▪ ≥ 18 yrs of age
▪ S. aureus isolated from one or more blood cultures
○ Exclusion criteria
▪ Antibiotic susceptibilities unavailable prior to death
▪ Care withdrawn prior to therapy being selected or targeted therapy
completed
● Statistical analysis: descriptive analysis

CONCLUSION

Appropriate

Inappropriate

Appropriate

Inappropriate

● S.aureus bacteremia was treated appropriately in majority of patients when
reviewing selection of antibiotics and duration of treatment. Practitioners will be
educated to re-emphasize longer treatment durations for patients with diabetes,
evidence of immunosuppression, metastatic infection, endocarditis, prosthetic or
intravascular devices, and lack of improvement within 72 hours of antibiotic
treatment.

Secondary Outcomes:

 Antimicrobial Stewardship Interventions: 5 out of 7 patients had documented interventions that were accepted
 Timing of ID Consultations: 4 out of 7 patients had an ID consult placed on the first day. ID was consulted on days 2,
3, or 5 for the remaining patients
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